Cargando…

Progress on Antiangiogenic Therapy for Patients with Malignant Glioma

Glioblastoma (GBM) is the most common primary brain tumor occurring in America. Despite recent advances in therapeutics, the prognosis for patients with newly diagnosed GBM remains dismal. As these tumors characteristically show evidence of angiogenesis (neovascularization) there has been great inte...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahluwalia, Manmeet S., Gladson, Candece L.
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2850510/
https://www.ncbi.nlm.nih.gov/pubmed/20379377
http://dx.doi.org/10.1155/2010/689018
_version_ 1782179786001481728
author Ahluwalia, Manmeet S.
Gladson, Candece L.
author_facet Ahluwalia, Manmeet S.
Gladson, Candece L.
author_sort Ahluwalia, Manmeet S.
collection PubMed
description Glioblastoma (GBM) is the most common primary brain tumor occurring in America. Despite recent advances in therapeutics, the prognosis for patients with newly diagnosed GBM remains dismal. As these tumors characteristically show evidence of angiogenesis (neovascularization) there has been great interest in developing anti-angiogenic therapeutic strategies for the treatment of patients with this disease and some anti-angiogenic agents have now been used for the treatment of patients with malignant glioma tumors. Although the results of these clinical trials are promising in that they indicate an initial therapeutic response, the anti-angiogenic therapies tested to date have not changed the overall survival of patients with malignant glioma tumors. This is due, in large part, to the development of resistance to these therapies. Ongoing research into key features of the neovasculature in malignant glioma tumors, as well as the general angiogenesis process, is suggesting additional molecules that may be targeted and an improved response when both the neovasculature and the tumor cells are targeted. Prevention of the development of resistance may require the development of anti-angiogenic strategies that induce apoptosis or cell death of the neovasculature, as well as an improved understanding of the potential roles of circulating endothelial progenitor cells and vascular co-option by tumor cells, in the development of resistance.
format Text
id pubmed-2850510
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-28505102010-04-08 Progress on Antiangiogenic Therapy for Patients with Malignant Glioma Ahluwalia, Manmeet S. Gladson, Candece L. J Oncol Review Article Glioblastoma (GBM) is the most common primary brain tumor occurring in America. Despite recent advances in therapeutics, the prognosis for patients with newly diagnosed GBM remains dismal. As these tumors characteristically show evidence of angiogenesis (neovascularization) there has been great interest in developing anti-angiogenic therapeutic strategies for the treatment of patients with this disease and some anti-angiogenic agents have now been used for the treatment of patients with malignant glioma tumors. Although the results of these clinical trials are promising in that they indicate an initial therapeutic response, the anti-angiogenic therapies tested to date have not changed the overall survival of patients with malignant glioma tumors. This is due, in large part, to the development of resistance to these therapies. Ongoing research into key features of the neovasculature in malignant glioma tumors, as well as the general angiogenesis process, is suggesting additional molecules that may be targeted and an improved response when both the neovasculature and the tumor cells are targeted. Prevention of the development of resistance may require the development of anti-angiogenic strategies that induce apoptosis or cell death of the neovasculature, as well as an improved understanding of the potential roles of circulating endothelial progenitor cells and vascular co-option by tumor cells, in the development of resistance. Hindawi Publishing Corporation 2010 2010-04-06 /pmc/articles/PMC2850510/ /pubmed/20379377 http://dx.doi.org/10.1155/2010/689018 Text en Copyright © 2010 M. S. Ahluwalia and C. L. Gladson. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Ahluwalia, Manmeet S.
Gladson, Candece L.
Progress on Antiangiogenic Therapy for Patients with Malignant Glioma
title Progress on Antiangiogenic Therapy for Patients with Malignant Glioma
title_full Progress on Antiangiogenic Therapy for Patients with Malignant Glioma
title_fullStr Progress on Antiangiogenic Therapy for Patients with Malignant Glioma
title_full_unstemmed Progress on Antiangiogenic Therapy for Patients with Malignant Glioma
title_short Progress on Antiangiogenic Therapy for Patients with Malignant Glioma
title_sort progress on antiangiogenic therapy for patients with malignant glioma
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2850510/
https://www.ncbi.nlm.nih.gov/pubmed/20379377
http://dx.doi.org/10.1155/2010/689018
work_keys_str_mv AT ahluwaliamanmeets progressonantiangiogenictherapyforpatientswithmalignantglioma
AT gladsoncandecel progressonantiangiogenictherapyforpatientswithmalignantglioma